If I’m reading this correctly, the $5M MNTA will receive from NVS for FDA approval of generic Lovenox is separate from the $163M in potential milestones MNTA can earn from NVS for regulatory and sales milestones pertaining to Copaxone in all jurisdictions and Lovenox in the EU. (The $5M milestone comes from NVS-MNTA’s 2003 agreement, while the $163M comes from the companies’ 2006 agreement.)
Market Data 
Markets 
AI
